Hyperlipidemia as a Risk Factor for Cardiovascular Disease

Published:December 05, 2012DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Primary Care: Clinics in Office Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Ambulatory Medical Care Survey: 2009 Summary Tables. In: National Ambulatory Medical Care Survey: 2009 Summary Tables, The Ambulatory and Hospital Care Statistics Branch of the Centers for Disease Control and Prevention’s National Center for Health Statistics, 2009, p. Table 16. Presence of selected chronic conditions at office visits, by patient age and sex: United States 2009. Available at: Accessed September 5, 2012.

        • National Cholesterol Education Program (NCEP) Expert Panel on Detection
        • Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
        Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report.
        Circulation. 2002; 106: 3143-3421
        • Murphy S.L.
        • Xu J.Q.
        • Kochanek K.D.
        Deaths: preliminary data for 2010. National vital statistics reports, Table B.
        National Center for Health Statistics, Hyattsville (MD)2012
      2. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.
        JAMA. 1984; 251: 351-364
      3. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.
        JAMA. 1984; 251: 365-374
        • Steinberg D.
        Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I.
        J Lipid Res. 2004; 45: 1583-1593
        • Steinberg D.
        Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans.
        J Lipid Res. 2005; 46: 179-190
        • Steinberg D.
        Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia.
        J Lipid Res. 2005; 46: 2037-2051
        • Steinberg D.
        The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it—almost.
        J Lipid Res. 2006; 47: 1-14
        • Steinberg D.
        Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy.
        J Lipid Res. 2006; 47: 1339-1351
      4. US Preventive Services Task Force. Screening for lipid disorders in adults. 2008. Available at: Accessed August 29, 2012.

      5. American Heart Association. Public cholesterol screening. 2011. Available at: Accessed September 5, 2012.

        • Semenkovich C.F.
        • Goldberg A.C.
        • Goldberg I.J.
        Disorders of lipid metabolism.
        in: Melmed S. Polonsky K.S. Larsen P.R. Williams textbook of endocrinology. 12th edition. W.B. Saunders, Philadelphia2011: 1655
        • Aberg J.A.
        Lipid management in patients who have HIV and are receiving HIV therapy.
        Endocrinol Metab Clin North Am. 2009; 38: 207-222
      6. Chapter 3.3 Assessment of cardiovascular risk.
        in: Cooper A. Nherera L. Calvert N. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. National Collaborating Centre for Primary Care and Royal College of General Practitioners, London2008: 49-54
        • Peters S.A.
        • den Ruijter H.M.
        • Bots M.L.
        • et al.
        Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review.
        Heart. 2012; 98: 177-184
        • Yeboah J.
        • McClelland R.L.
        • Polonsky T.S.
        • et al.
        Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.
        JAMA. 2012; 308: 788-795
        • Boekholdt S.M.
        • Arsenault B.J.
        • Mora S.
        • et al.
        Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
        JAMA. 2012; 307: 1302-1309
        • Di Angelantonio E.
        • Gao P.
        • Pennells L.
        • et al.
        Lipid-related markers and cardiovascular disease prediction.
        JAMA. 2012; 307: 2499-2506
        • Grundy S.M.
        Use of emerging lipoprotein risk factors in assessment of cardiovascular risk.
        JAMA. 2012; 307: 2540-2542
        • Balk E.M.
        • Lau J.
        • Goudas L.C.
        • et al.
        Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review.
        Ann Intern Med. 2003; 139: 670-682
      7. ATP-III at-a-glance: quick desk reference 2001. Available at: Accessed September 5, 2012.

        • Davidson M.H.
        • Maki K.C.
        • Pearson T.A.
        • et al.
        Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
        Am J Cardiol. 2005; 96: 556-563
        • Centers for Disease Control and Prevention
        QuickStats: average total cholesterol level among men and women.
        Department of Health and Human Services, Atlanta (GA)2009 (p. 1045)
        • Curioni C.C.
        • Lourenco P.M.
        Long-term weight loss after diet and exercise: a systematic review.
        Int J Obes (Lond). 2005; 29: 1168-1174
        • Makris A.
        • Foster G.D.
        Dietary approaches to the treatment of obesity.
        Psychiatr Clin North Am. 2011; 34: 813-827
        • Hemphill L.C.
        Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis.
        J Clin Lipidol. 2010; 4: 346-349
        • Oosterveer D.M.
        • Versmissen J.
        • Yazdanpanah M.
        • et al.
        Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis.
        Atherosclerosis. 2009; 207: 311-317
        • Sharma M.
        • Ansari M.T.
        • Abou-Setta A.M.
        • et al.
        Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
        Ann Intern Med. 2009; 151: 622-630
        • Stevinson C.
        • Pittler M.H.
        • Ernst E.
        Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials.
        Ann Intern Med. 2000; 133: 420-429
        • Wider B.
        • Pittler M.H.
        • Thompson-Coon J.
        • et al.
        Artichoke leaf extract for treating hypercholesterolaemia.
        Cochrane Database Syst Rev. 2009; (CD003335)
        • Nies L.K.
        • Cymbala A.A.
        • Kasten S.L.
        • et al.
        Complementary and alternative therapies for the management of dyslipidemia.
        Ann Pharmacother. 2006; 40: 1984-1992
        • Nissen S.E.
        • Wolski K.
        Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
        N Engl J Med. 2007; 356: 2457-2471
        • Jonas D.
        • Van Scoyoc E.
        • Gerrald K.
        • et al.
        Drug class review: newer diabetes medications, TZDs, and combinations: final original report.
        ([Internet]) Oregon Health & Science University, Portland (OR)2011 (Available at:) (Accessed August 31, 2012)
        • Cannon C.P.
        • Steinberg B.A.
        • Murphy S.A.
        • et al.
        Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.
        J Am Coll Cardiol. 2006; 48: 438-445
        • Nissen S.E.
        • Nicholls S.J.
        • Sipahi I.
        • et al.
        Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
        JAMA. 2006; 295: 1556-1565
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Sattar N.
        • Preiss D.
        • Murray H.M.
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        • Preiss D.
        • Seshasai S.R.
        • Welsh P.
        • et al.
        Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
        JAMA. 2011; 305: 2556-2564
        • Preiss D.
        • Tikkanen M.J.
        • Welsh P.
        • et al.
        Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.
        JAMA. 2012; 308: 804-811
        • Sharma M.
        • Ansari M.T.
        • Soares-Weiser K.
        • et al.
        Comparative effectiveness of lipid-modifying agents.
        (Prepared by the University of Ottawa Evidence-based Practice Center under contract No. 290-02-0021)in: Comparative effectiveness review. Agency for Healthcare Research and Quality, Rockville (MD)2009: ES1-ES14 (Available at:) (Accessed September 5, 2012)
        • Conly J.
        • Clement F.
        • Tonelli M.
        • et al.
        Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk.
        CMAJ. 2011; 183: E1180-E1188
        • Boden W.E.
        • Probstfield J.L.
        • Anderson T.
        • et al.
        Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
        N Engl J Med. 2011; 365: 2255-2267
        • Ghosh R.K.
        • Ghosh S.M.
        Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
        Curr Clin Pharmacol. 2012; 7: 102-110
        • Voight B.F.
        • Peloso G.M.
        • Orho-Melander M.
        • et al.
        Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.
        Lancet. 2012; 380: 572-580
        • Ginsberg H.N.
        • Elam M.B.
        • Lovato L.C.
        • et al.
        Effects of combination lipid therapy in type 2 diabetes mellitus.
        N Engl J Med. 2010; 362: 1563-1574
        • Keech A.
        • Simes R.J.
        • Barter P.
        • et al.
        Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
        Lancet. 2005; 366: 1849-1861
        • Gregson J.
        • Stirnadel-Farrant H.A.
        • Doobaree I.U.
        • et al.
        Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature.
        Atherosclerosis. 2012; 225: 11-21
        • Nordestgaard B.G.
        • Chapman M.J.
        • Ray K.
        • et al.
        Lipoprotein(a) as a cardiovascular risk factor: current status.
        Eur Heart J. 2010; 31: 2844-2853
        • Teramoto T.
        The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
        Expert Opin Pharmacother. 2012; 13: 859-865
        • Maruyama T.
        • Takada M.
        • Nishibori Y.
        • et al.
        Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study.
        Circ J. 2011; 75: 1951-1959
        • Nicholls S.J.
        • Ballantyne C.M.
        • Barter P.J.
        • et al.
        Effect of two intensive statin regimens on progression of coronary disease.
        N Engl J Med. 2011; 365: 2078-2087